Fractyl Health, Inc.

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for obesity and type 2 diabetes. Its current work centers on approaches that address the root causes of metabolic disease rather than only managing symptoms, with a primary emphasis on gut-based therapies. The company’s lead product candidate, Revita, is an investigational outpatient procedural therapy designed to remodel dysfunctional duodenal tissue and improve metabolic signaling. Fractyl Health is also developing Rejuva, a pancreatic gene therapy platform aimed at supporting longer-term metabolic control. Based in Burlington, Massachusetts, Fractyl Health operates in the healthcare and biotechnology space, where it is working on device- and therapy-based solutions for serious chronic metabolic conditions.